ArticleCureus2025
Clinical Impact of Radiotherapy in Steroid-Refractory Graves' Orbitopathy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGraves' orbitopathy (GO) is the most common extrathyroidal manifestation of Graves' disease. Treatment options depend on its severity. Orbital radiotherapy is recommended as a second-line treatment in patients who are refractory or intolerant of glucocorticoid treatment. This study aimed to analyze the clinical outcome after radiotherapy in patients diagnosed with Graves' orbitopathy who are refractory to glucocorticoids.
methodsWe retrospectively analyzed the clinical data of 10 patients with Graves' orbitopathy who did not respond to glucocorticoid management. They were treated with retrobulbar radiotherapy between January 2010 and January 2021, with a schedule of 20 Gy in 10 fractions. The variables analyzed were ocular movements, exophthalmos, diplopia, retrobulbar pain, ectropion, visual acuity, eyelid closure, and conjunctival hyperemia.
resultsCategorical variables were compared before and after radiotherapy treatment in the evaluated patients. A statistically significant response to radiotherapy was observed in the following outcomes: exophthalmos (p=0.005) and retrobulbar pain (p=0.04). One case of local recurrence was observed at 20 months of follow-up, achieving a local control of 90%. Recurrence-free survival (RFS) at one, three, and five years was 100%, 90%, and 90%, respectively.
conclusionsRadiotherapy is an effective and well-tolerated treatment that reduces exophthalmos and retrobulbar pain and can prevent disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.